Find, compare & contact
Chlorfenson
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Chlorfenson API 80-33-1?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Chlorfenson. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Chlorfenson
- Synonyms:
- 4-Chlorophenyl 4-chlorobenzenesulfonate , Ester sulfonate
- Cas Number:
- 80-33-1
- DrugBank number:
- DB05377
- Unique Ingredient Identifier:
- LW65NJ3YWV
General Description:
Chlorfenson, identified by CAS number 80-33-1, is a notable compound with significant therapeutic applications. Chlorfenson is developed by Moberg Derma for the treatment of onychomycosis (nail fungus) as the primary indication.
Indications:
This drug is primarily indicated for: Investigated for use/treatment in fungal infections. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Mechanism of Action:
Chlorfenson functions by: Chlorfenson is a topical solution applied once-daily on affected nails during treatment periods of 3-6 months. In pilot studies, Chlorfenson has shown promising results and provides important benefits compared to existing treatment alternatives. There is a significant need for more efficacious topical treatments. For more severe cases of the disease where more than 50% of the nail is affected, the only available options are oral anti-fungals which are associated with a certain risk for severe side effects. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Chlorfenson belongs to the class of organic compounds known as benzenesulfonate esters. These are arenesulfonate esters that result from the formal condensation of the hydroxy group of an alcohol, enol, phenol or heteroarenol with benzenesulfonic acid, classified under the direct parent group Benzenesulfonate esters. This compound is a part of the Organic compounds, falling under the Benzenoids superclass, and categorized within the Benzene and substituted derivatives class, specifically within the Benzenesulfonic acids and derivatives subclass.
Categories:
Chlorfenson is categorized under the following therapeutic classes: Arylsulfonates, Arylsulfonic Acids, Benzene Derivatives, Sulfonic Acids, Sulfur Acids, Sulfur Compounds. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Chlorfenson is a type of Antifungals
Antifungals are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) designed to combat fungal infections. These medications are developed to target and eliminate fungi, including yeasts and molds, which can cause a range of diseases in humans and animals.
Antifungals work by interfering with specific components or processes essential for fungal growth and reproduction. They may inhibit the synthesis of fungal cell walls or disrupt the production of ergosterol, a crucial component of fungal cell membranes. By targeting these key mechanisms, antifungal APIs effectively hinder the growth and spread of fungal infections.
The diversity within the antifungal category is reflected in the various classes of antifungal APIs available. Azoles, polyenes, echinocandins, and allylamines are common classes of antifungals. Each class exhibits unique mechanisms of action and targets specific types of fungi. This diversity enables healthcare professionals to tailor treatment plans to the specific fungal infection, optimizing therapeutic outcomes.
Antifungal APIs find application in various pharmaceutical formulations, including oral medications, topical creams, ointments, and intravenous solutions. They are crucial for the treatment of common fungal infections like athlete's foot, ringworm, vaginal yeast infections, and oral thrush. Additionally, antifungals play a crucial role in managing serious systemic fungal infections that can pose significant health risks, especially in immunocompromised individuals.
Overall, antifungal APIs are indispensable tools in the fight against fungal infections, offering effective treatment options and improving the quality of life for patients suffering from these conditions. With ongoing research and development, the antifungal category continues to evolve, providing innovative solutions to combat the ever-changing landscape of fungal pathogens.
